Dana Flanders
Stock Analyst at Guggenheim
(n/a)
# 4,407
Out of 4,761 analysts
8
Total ratings
n/a
Success rate
-30.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dana Flanders
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SCYX SCYNEXIS | Initiates: Buy | $25 | $1.07 | +2,236.45% | 1 | Jan 22, 2021 | |
| PCRX Pacira BioSciences | Initiates: Neutral | n/a | $25.16 | - | 1 | May 27, 2020 | |
| HRTX Heron Therapeutics | Initiates: Buy | $24 | $1.73 | +1,287.28% | 1 | May 27, 2020 | |
| COLL Collegium Pharmaceutical | Initiates: Neutral | n/a | $29.13 | - | 1 | May 27, 2020 | |
| LGND Ligand Pharmaceuticals | Initiates: Neutral | n/a | $120.67 | - | 2 | Mar 10, 2020 | |
| EBS Emergent BioSolutions | Upgrades: Buy | $60 → $75 | $7.71 | +872.76% | 2 | Nov 2, 2018 |
SCYNEXIS
Jan 22, 2021
Initiates: Buy
Price Target: $25
Current: $1.07
Upside: +2,236.45%
Pacira BioSciences
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $25.16
Upside: -
Heron Therapeutics
May 27, 2020
Initiates: Buy
Price Target: $24
Current: $1.73
Upside: +1,287.28%
Collegium Pharmaceutical
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $29.13
Upside: -
Ligand Pharmaceuticals
Mar 10, 2020
Initiates: Neutral
Price Target: n/a
Current: $120.67
Upside: -
Emergent BioSolutions
Nov 2, 2018
Upgrades: Buy
Price Target: $60 → $75
Current: $7.71
Upside: +872.76%